Showing 2581-2590 of 3889 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0709_04-php/22799/How Viable is Pay-for-Performance in Dermatology?
https://practicaldermatology.com/topics/general-topics/PD0509_03-php/22825/Though Pay-for-Performance has affected primary care medicine for years, it has only recently expanded into specialized medicine. Experts discuss its eventual impact on dermatology.Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0509_05-php/22827/Is Topical Therapy for Psoriasis Resurging?
https://practicaldermatology.com/topics/psoriasis/PD0409_03-php/22841/While biologics have changed the way patients and physicians think about psoriasis, topical therapy remains important for a majority of patients.Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0409_05-php/22843/What Do New PhRMA Guidelines Mean for Dermatology?
https://practicaldermatology.com/topics/general-topics/PD0309_04-php/22858/Revisions to the "Code on Interactions" are taking effect, but what do they really mean for the typical clinician?Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0309_06-php/22860/You Want to Start A New Practice: Now What?
https://practicaldermatology.com/topics/general-topics/PD0309_12-php/22866/After making the decision to start a practice, constructing a solid business plan and financial overview is critical.- ASLMS to Honor David J. Cuccia, PhDhttps://practicaldermatology.com/news/20120314-aslms_to_honor_david_j_cuccia_phd/2459844/David J. Cuccia, Ph.D, Chief Technology Officer and CEO at Modulated Imaging, Inc. Irvine, California, will receive the 2012 Dr. Horace Furumoto Innovations Professional Development Grant at the Annual Conference of the American Society for Laser Medicine and Surgery
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select